Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Summary

The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications